Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study - 23/11/23
, Mahmood Muazu Dalhat, FWACP b, Ballah Akawu Denue, ProfFWACP c, Mildred Okowa, MBBS d, Nneka Marian Chika-Igwenyi, MBBS e, Hakeem Abiola Yusuff, MPH f, Umenzekwe Chukwudi Christian, FMCP g, Olukemi Adekanmbi, FACP h, Anastacia Okwudili Ojimba, FMCPH i, John Tunde Aremu, FWACP j, Kambai Lalus Habila, MSc k, Sebastine Oseghae Oiwoh, FWACP l, Ekaete Alice Tobin, FWACP m, Simon Mafuka Johnson, FWACP n, Abimbola Olaitan, MBBS o, Chizaram Onyeaghala, MBBS p, Simji Samuel Gomerep, FWACP q, Datonye Alasia, ProfFWACP p, Asukwo E Onukak, FWACP r, Juliet Mmerem, FWACP s, Uche Unigwe, FWACP s, Olanrewaju Falodun, FMCP t, Vivian Kwaghe, FWACP u, Sati Klein Awang, FWACP v, Mogaji Sunday, MBBS w, Chiedozie James Maduka, FWACP x, Aliyu Mamman Na'uzo, FWACP y, Sampson Omagbemi Owhin, FMCP z, Abdullahi Asara Mohammed, FWACP aa, Mukhtar Abdulmajid Adeiza, FWACP aaon behalf of the
Nigerian Infectious Diseases Society Mpox Study Group†
Summary |
Background |
Research from sub-Saharan Africa that contributes to our understanding of the 2022 mpox (formerly known as monkeypox) global outbreak is insufficient. Here, we describe the clinical presentation and predictors of severe disease among patients with mpox diagnosed between Feb 1, 2022, and Jan 30, 2023 in Nigeria.
Methods |
We did a cohort study among laboratory-confirmed and probable mpox cases seen in 22 mpox-treatment centres and outpatient clinics across Nigeria. All individuals with confirmed and probable mpox were eligible for inclusion. Exclusion criteria were individuals who could not be examined for clinical characterisation and those who had unknown mortality outcomes. Skin lesion swabs or crust samples were collected from each patient for mpox diagnosis by PCR. A structured questionnaire was used to document sociodemographic and clinical data, including HIV status, complications, and treatment outcomes from the time of diagnosis to discharge or death. Severe disease was defined as mpox associated with death or with a life-threatening complication. Two logistic regression models were used to identify clinical characteristics associated with severe disease and potential risk factors for severe disease. The primary outcome was the clinical characteristics of mpox and disease severity.
Findings |
We enrolled 160 people with mpox from 22 states in Nigeria, including 134 (84%) adults, 114 (71%) males, 46 (29%) females, and 25 (16%) people with HIV. Of the 160 patients, distinct febrile prodrome (n=94, 59%), rash count greater than 250 (90, 56%), concomitant varicella zoster virus infection (n=48, 30%), and hospital admission (n=70, 48%) were observed. Nine (6%) of the 160 patients died, including seven (78%) deaths attributable to sepsis. The clinical features independently associated with severe disease were a rash count greater than 10 000 (adjusted odds ratio 26·1, 95% CI 5·2–135·0, p<0·0001) and confluent or semi-confluent rash (6·7, 95% CI 1·9–23·9). Independent risk factors for severe disease were concomitant varicella zoster virus infection (3·6, 95% CI 1·1–11·5) and advanced HIV disease (35·9, 95% CI 4·1–252·9).
Interpretation |
During the 2022 global outbreak, mpox in Nigeria was more severe among those with advanced HIV disease and concomitant varicella zoster virus infection. Proactive screening, management of co-infections, the integration and strengthening of mpox and HIV surveillance, and preventive and treatment services should be prioritised in Nigeria and across Africa.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 12
P. 1418-1428 - décembre 2023 Retour au numéro
Article précédent
- Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
- Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Francis Kiweewa, Immaculate Nakabuye, Galina V Yamshchikov, Charla Andrews, Mark O'Callahan, Larisa Strom, Steven Schech, Leigh Anne Eller, Erica L Sondergaard, Paul T Scott, Mihret F Amare, Kayvon Modjarrad, Amir Wamala, Allan Tindikahwa, Ezra Musingye, Jauhara Nanyondo, Martin R Gaudinski, Ingelise J Gordon, LaSonji A Holman, Jamie G Saunders, Pamela J M Costner, Floreliz H Mendoza, Myra Happe, Patricia Morgan, Sarah H Plummer, Somia P Hickman, Sandra Vazquez, Tamar Murray, Jamilet Cordon, Caitlyn N M Dulan, Ruth Hunegnaw, Manjula Basappa, Marcelino Padilla, Suprabhath R Gajjala, Phillip A Swanson, Bob C Lin, Emily E Coates, Jason G Gall, Adrian B McDermott, Richard A Koup, John R Mascola, Aurélie Ploquin, Nancy J Sullivan, Hannah Kibuuka, Julie A Ake, Julie E Ledgerwood, RV 508 Study Team, Jaqueline Namugabo, Claire Beingana, Maureen G. Mukyala, Joseph Wandege, Christine Nanteza, Brenda Atwijuka, Juliet Kizanye, Gertrude Nassanga, Joanita Namuli, Herbert Kityo, Mathias Ssekitoleko, Roy Nassaka, Hilda Mutebe, Mable Kabahubya, Alicia T. Widge, Sarah E. O'Connell, Obrimpong Amoa-Awua, Sandeep R. Narpala, Britta Flach, Josephine Cox, Allison Beck, Mercy Guech, Ellie Seo, Judy A. Stein
- Simian malaria: a narrative review on emergence, epidemiology and threat to global malaria elimination
- Kimberly M Fornace, Gabriel Zorello Laporta, Indra Vythilingham, Tock Hing Chua, Kamruddin Ahmed, Nantha K Jeyaprakasam, Ana Maria Ribeiro de Castro Duarte, Amirah Amir, Wei Kit Phang, Chris Drakeley, Maria Anice M Sallum, Yee Ling Lau
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?